No abstract

No abstract

On long-term followup the 1993 modification of the Ultrex cylinders appears to have significantly decreased the propensity of cylinder failure of the pre-modification device.

On long-term followup the 1993 modification of the Ultrex cylinders appears to have significantly decreased the propensity of cylinder failure of the pre-modification device.

each represents (37.1%), followed by group D (25.8%). Among the fecal isolates phylogroup A (50.0%) was still the most prevalent followed by groups D (30.0%), B1 (13.3%), and B2 (6.7%). Significantly, phylogenetic group B1 was more prevalent in the fecal isolates, while, group B2 was more common in bladder isolates. No significant difference present as regard the distribution of the phylogroups when comparing the neobladder isolates either with the bladder or the fecal ones. Among the total studied 100 E. coli isolates, 77 isolates (77%) carried at least one PAI marker among which a total of 129 PAIs were detected including 25 fecal isolates (83.3%) carrying 36 PAIs, 29 bladder isolates (82.9%) carrying 49 PAIs, and 23 neobladder isolates (65.7%) carrying 44 PAIs (p > 0.05). The most prevalent PAIs were PAI IV 536 (56%) and PAI II CFT073 (37%), respectively, while PAI II J96 was not detected in any of the studied isolates. Only PAI IV 536 was significantly more prevalent in the fecal isolates (76.7%) than in UPEC (74.3%) and neobladder isolates (48.6%). 14 isolates (40%) carried 2 or more PAIs in each of neobladder and bladder isolates compared to 10 fecal isolates (33.3%) (p > 0.05). The maximum number of PAIs detected per isolate was four (included II 536 , III 536 , IV 536 , II CFT073 ) and was found only in one isolate from noebladder source and belonging to the phylogenetic group B2.CONCLUSIONS: While distinct, the distribution of phenotypic virulence traits among neobladder isolates were intermediary between both UPEC and the fecal isolates, revealing its ability to colonize the ileal neobladder but rarely progress to symptomatic UTI. The predominant phylogenetic group among the neobladder isolates were A and D, the same as in fecal isolates. The prevalence of PAIs carriage among neobladder E. coli isolates was less than that detected among UPEC and fecal isolates.

No abstract

HCO3(-) secretion across in vitro duodenal mucosa of Rana catesbeiana was investigated under baseline conditions and during secretory stimulation. Baseline secretion was abolished by removal of CO2-HCO3(-)and reduced approximately 60% by removal of nutrient Na+, but was not sensitive to changes in Cl- or K+. Baseline secretion was not directly altered by exposure to 10(-3) M amiloride or 10(-3) M H2DIDS (dihydro-4,4'-diisothiocyanostilbene-2,2'-disulfonic acid) in the nutrient solution and only mildly reduced by acetazolamide. Following removal and restoration of Na+, recovery of secretion was impaired by exposure to acetazolamide (5 x 10(-4) M) or H2DIDS (5 x 10(-4) M) in the nutrient solution. Secretion stimulated by glucagon (10(-6) M) or 16,16-dimethyl prostaglandin E2 (10 microg.mL(-1)) was markedly attenuated by removal of Na+ or by exposure to H2DIDS, but secretion was not altered by acetazolamide (5 x 10(-4) M) or nutrient amiloride (1 mM). Thus, the HCO3(-) that is secreted under nonstimulated conditions derives partly from basolateral Na(+)-dependent uptake and partly from cellular CO2 hydration. Secretagogue-stimulated secretion by duodenal surface epithelium depends on stilbene-sensitive Na+(HCO3(-))n uptake across the basolateral membrane.

Since the introduction of sildenafil citrate, oral systemic therapy has become the first line of therapy for men with erectile dysfunction (ED). Men who are not candidates for or who fail treatment with an oral agent may choose second-line therapies such as intraurethral prostaglandins, penile injection therapy, sex therapy, or a vacuum erection device. These secondline therapies may be unpalatable or inadequate for some men, and these men constitute the candidates for surgical intervention for ED. This article reviews surgical management of vascular ED, surgical management of Peyronie's disease, and penile prosthesis implantation. At the current time, the appropriate candidate for penile revascularization is a young man with proven arterial insufficiency resulting from pelvic trauma. Results in other populations are disappointing. Peyronie's disease with curvature significant enough to interfere with intercourse may be managed with tunical lengthening or shortening procedures in potent men and with prosthetic implantation in men with ED. Modern three-piece penile prostheses are associated with excellent device reliability, high rates of patient satisfaction, and acceptably low complication rates.